Sutent sunitinib: Phase III discontinued

Pfizer discontinued the double-blind, international Phase III SUN 1120 trial after an interim analysis by the study's IDMC showed that Sutent plus prednisone was unlikely to meet the primary endpoint of significantly improving OS vs. placebo plus prednisone. No new or unexpected safety issues were identified. The trial enrolled 873 patients with advanced CRPC that had progressed despite treatment with a docetaxel-based chemotherapy regimen. ...